Effects of nebivolol on biomarkers in elderly patients with heart failure

International Journal of Cardiology

Volumn 175, Issue 2, 2014, Pages 253-260

  Taneja, Anil K ^a   Gaze, David ^b   Coats, Andrew J S ^c,i,j   Dumitrascu, Dan ^d   Spinarova, Lenka ^e   Collinson, Paul ^f   Roughton, Michael ^g   Flather, Marcus D ^h,k  

^a WHIPPS CROSS UNIVERSITY HOSPITAL   (United Kingdom)

^b ST GEORGE S HOSPITAL   (United Kingdom)

^c MONASH UNIVERSITY   (Australia)

^d Department of Prosthodontics   (Romania)

^e ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^f ST GEORGE'S UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^g NOVARTIS PHARMA AG   (Switzerland)

^h UNIVERSITY OF EAST ANGLIA   (United Kingdom)

ⁱ UNIVERSITY OF MELBOURNE   (Australia)

^j UNIVERSITY OF WARWICK   (United Kingdom)

^k ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Beta blockers in heart failure; Nebivolol; Neurohormones; NT Pro BNP and beta blockers; SENIORS substudy

Indexed keywords

6 N,N' DIMETHYLARGININE; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ARGININE; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; CITRULLINE; ENDOTHELIN 1; FAS ANTIGEN; FAS LIGAND; N(G),N(G) DIMETHYLARGININE; NEBIVOLOL; NITRIC OXIDE; NORADRENALIN; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BENZOPYRAN DERIVATIVE; BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CYTOKINE; ETHANOLAMINE DERIVATIVE;

AGED; ARTICLE; DIABETES MELLITUS; DRUG EFFECT; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; URIC ACID BLOOD LEVEL; BLOOD; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; INTERNATIONAL COOPERATION; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VERY ELDERLY;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; AGED; AGED, 80 AND OVER; BENZOPYRANS; BIOLOGICAL MARKERS; CYTOKINES; DOUBLE-BLIND METHOD; ETHANOLAMINES; FEMALE; HEART FAILURE; HUMANS; INTERNATIONALITY; MALE; NEUROTRANSMITTER AGENTS; TREATMENT OUTCOME;

EID: 84904250724     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2014.05.018     Document Type: Article

References (40)

1. M.C. Shibata, M.D. Flather, and D. Wang Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure Eur J Heart Fail 3 3 Jun 2001 351 357
2. M.D. Flather, M.C. Shibata, and A.J. Coats et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure Eur Heart J 26 3 Feb 2005 215 225
3. M.R. Bristow Mechanism of action of beta-blocking agents in heart failure Am J Cardiol 80 11A Dec 4 1997 26L 40L
4. R.P. Mason, T.D. Giles, and J.R. Sowers Evolving mechanisms of action of beta blockers: focus on nebivolol J Cardiovasc Pharmacol 54 2 Aug 2009 123 128
5. S. Koichi, S. Yoshihiko, O. Takeshi, O. Toshiaki, S. Kohji, and T. Teruo Ongoing myocardial damage in chronic heart failure is related to activated tumor necrosis factor and Fas/Fas ligand system Circ J 68 2004 747 750
6. A. Parenti, S. Filippi, and S. Amerini Inositol phosphate metabolism and nitric oxide synthase activity in endothelial cells are involved in the vasorelaxant activity of nebivolol J Pharmacol Exp Ther 292 2000 698 703
7. P. Vallance, A. Leone, A. Calver, J. Collier, and S. Moncada Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure Lancet 339 1992 572 575
8. R.H. Boeger, S.M. Bode-boeger, and A. Szuba et al. Asymmetric dimethylamine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolaemia Circulation 98 1998 1842 1847
9. O. Kamp, M. Metra, and S. Bugatti et al. Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release Drugs 70 1 2010 41 56
10. M.C. Shibata, M.D. Flather, and m Bohm et al. Study of the effects of nebivolol intervention on outcomes and rehospitalisation in seniors with heart failure Int J Cardiol 86 1 Nov 2002 77 85
11. B. Stanek, B. Frey, and M. Hülsmann et al. Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction JACC 38 2 2001 436 442
12. P. de Groote, P. Delour, and N. Lamblin et al. Effects of bisoprolol in patients with stable congestive heart failure Ann Cardiol Angeiol (Paris) 53 4 Jul 2004 167 170
13. A. Yoshizawa, A.T. Yoshikawa, and W. Nakamura et al. Brain natriuretic peptide response is heterogeneous during beta-blocker therapy for congestive heart failure J Card Fail 10 4 2004
14. R.P. Frantz, L.J. Olson, and D. Grill et al. Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure Am Heart J 149 3 Mar 2005 541 547
15. R. Berger, M. Huelsman, and K. Stecker et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure Circulation 105 2002 2391 2396
16. A.M. Richards, R. Doughty, and M.G. Nicholls et al. Prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction J Am Coll Cardiol 37 7 2001 1781 1787
17. T. Yoshimoto, M. Naruse, and A. Tanabe et al. Potentiation of natriuretic peptide action by the beta-adrenergic blocker carvedilol in hypertensive rats: a new antihypertensive mechanism Endocrinology 139 1998 81 88
18. A.H. van den Meiracker, T.W. Lameris, L.L. van de Ven, and F. Boomsma Increased plasma concentration of natriuretic peptides by selective beta1-blocker bisoprolol J Cardiovasc Pharmacol 42 4 Oct 2003 462 468
19. N. Li, Y. Li, and F. Wang et al. Does NT-ProBNP remain a sensitive biomarker for chronic heart failure after administration of a beta-blocker? Clin Cardiol 30 9 Sep 2007 469 474
20. F. Hartmann, M. Packer, and A.J. Coats et al. Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial Circulation 110 13 Sep 28 2004 1780 1786
21. F. Hartmann, M. Packer, and A.J.S. Coats et al. NT-Pro BNP in severe chronic heart failure: rationale, design and preliminary results of the COPERNICUS NT-Pro BNP substudy Eur J Heart Fail 6 3 2004 343 350
22. J.W. Fung, C.M. Yu, and G. Yip et al. Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure Am J Cardiol 92 4 Aug 15 2003 406 410
23. J. Rosenberg, F. Gustafsson, W.J. Remme, G.A. Riegger, and P.R. Hildebrandt Effect of beta-blockade and ACE inhibition on B-type natriuretic peptides in stable patients with systolic heart failure Cardiovasc Drugs Ther 22 4 2008 305 331
24. J.G.F. Cleland, S. Ray, and J. Dalle Mulle Can natriuretic peptides be used to monitor response to carvedilol in patients with ischaemic left ventricular systolic dysfunction? Circulation 106 Suppl. II 2006 [Abstract 3487]
25. F. Gundogdu, E. Bozkurt, and A. Kizitunc et al. The effect of beta-blocker (carvedilol) therapy on N-terminal pro-brain natriuretic peptide levels and echocardiographic findings in patients with congestive heart failure Echocardiography 24 2 Feb 2007 113 117
26. G. Lars Olsson, Kari Swedberg, John G.F. Cleland, et al. Prognostic importance of plasma NT-ProBNP in chronic heart failure in patients treated with a β-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) Eur J Heart Fail 9 8 2007 795 801
27. 2 + infusion, and aortic constriction in pigs Circ Res 68 1991 638 644
28. The RESOLVD Investigators Effects of metoprolol CR in patients with ischemic and dilated cardiomyopathy: the randomized evaluation of strategies for left ventricular dysfunction pilot study Circulation 101 2000 378 384
29. A. Luchner, J.C. Burnett Jr., M. Jougasaki, H. Hense, G.A.J. Riegger, and H. Schunkert Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study J Am Coll Cardiol 32 1998 1839 1844
30. A.G. Semenov, and K.R. Seferian Biochemistry of the human B-type natriuretic peptide precursor and molecular aspects of its processing Clin Chim Acta 412 2011 850 860
31. R.H. Ritchie, A.C. Rosenkranz, and D.M. Kaye B-type natriuretic peptide: endogenous regulator of myocardial structure, biomarker and therapeutic target Curr Mol Med 9 2009 814 825
32. R. Troughton, G.M. Felker, and J.L. Januzzi Natriuretic peptide-guided heart failure management Eur Heart J 35 1 2014 16 24
33. R. Ferrari, T. Bachetti, and R. Confortini et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure Circulation 92 1995 1479 1486
34. Lukas E. Spieker, and Thomas F. Lüscher Endothelin receptor antagonists in heart failure - a refutation of a bold conjecture? Eur J Heart Fail 5 4 August 2003 415 417
35. A. Niessner, P.J. Hohensinner, and K. Rychli et al. Prognostic value of apoptosis markers in advanced heart failure patients Eur Heart J 30 2009 789 796
36. M. Scherrer-Crosbie, R. Ullrich, and K.D. Bloch et al. Endothelial nitric oxide synthase limits left ventricular remodelling after myocardial infarction in mice Circulation 104 2001 1286 1291
37. M. Usui, H. Matsuoka, H. Miyazaki, S. Ueda, S. Okuda, and T. Imaizumi Increased endogenous NO synthase inhibitor in patients with congestive heart failure Life Sci 62 1998 2425 2430
38. L. Kalinowski, L.W. Dobrucki, and M. Szczepanska-Konkel et al. Third generation beta-blockers stimulates nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action Circulation 107 2003 2747 2752
39. K.E. Fayers, M.H. Cummings, K.M. Shaw, and D.W. Laight Nitrate tolerance and the links with endothelial dysfunction and oxidative stress Br J Pharmacol 56 6 December 2003
40. A.M. Richards, R. Doughty, and M.G. Nicholls et al. Neurohormonal prediction of benefit from Carvedilol in ischaemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group Circulation 99 6 Feb 16 1999 786 792